Overview

A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 90 healthy subjects. The primary objective is to evaluate the safety and tolerability of TQ-A3334 tablets after multiple doses in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.